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Abstract
Background: Patients with ectopic pregnancy (EP) and low serum hCG concentrations and
women with a pregnancy of unknown location (PUL) and plateauing serum hCG levels are
commonly treated with systemic methotrexate (MTX). However, there is no evidence that
treatment in these particular subgroups of women is necessary as many of these early EPs may
resolve spontaneously. The aim of this study is whether expectant management in women with EP
or PUL and with low but plateauing serum hCG concentrations is an alternative to MTX treatment
in terms of treatment success, future pregnancy, health related quality of life and costs.
Methods/Design: A multicentre randomised controlled trial in The Netherlands.
Hemodynamically stable patients with an EP visible on transvaginal ultrasound and a plateauing
serum hCG concentration < 1,500 IU/L or with a persisting PUL with plateauing serum hCG
concentrations < 2,000 IU/L are eligible for the trial. Patients with a viable EP, signs of tubal rupture/
abdominal bleeding, or a contra-indication for MTX will not be included. Expectant management is
compared with systemic MTX in a single dose intramuscular regimen (1 mg/kg) in an outpatient
setting. Serum hCG levels are monitored weekly; in case of inadequately declining, systemic MTX
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BMC Women's Health 2008, 8:10 http://www.biomedcentral.com/1472-6874/8/10is installed or continued. In case of hemodynamic instability and/or signs of tubal rupture, surgery
is performed. The primary outcome measure is an uneventful decline of serum hCG to an
undetectable level by the initial intervention. Secondary outcomes are (re)interventions (additional
systemic MTX injections and/or surgery), treatment complications, health related quality of life,
financial costs, and future fertility. Analysis is performed according to the intention to treat
principle. Quality of life is assessed by questionnaires before and at three time points after
randomisation. Costs are expressed as direct costs with data on costs and used resources in the
participating centres. Fertility is assessed by questionnaires after 6, 12, 18 and 24 months. Patients'
preferences will be assessed using a discrete choice experiment.
Discussion: This trial will provide guidance on the present management dilemmas in women with
EPs and PULs with low and plateauing serum hCG concentrations.
Trial registration: Current Controlled Trials ISRCTN 48210491
Background
In industrialized countries the incidence of ectopic preg-
nancy (EP) is approximately 1 to 2% of all pregnancies [1-
4]. EP is usually diagnosed by non-invasive methods, i.e.
by sensitive pregnancy tests in urine and serum, and high
resolution transvaginal sonography (TVS), which have
been integrated in reliable diagnostic algorithms. These
algorithms, in combination with increased awareness and
knowledge of risk factors among both clinicians and
patients, have enabled an early and accurate diagnosis of
EP [5-7].
As a consequence, the clinical presentation of EP has
changed from a life threatening disease, necessitating
emergency surgery, to a more benign condition in fre-
quently asymptomatic patients for whom non-surgical
treatment options are available, i.e. medical treatment
with systemic methotrexate (MTX) treatment or expectant
management.
MTX can be administered systemically in a multiple dose
regimen (MTX 1.0 mg/kg intramuscularly (im) day 0, 2, 4,
6, alternated with folinic acid 0.1 mg/kg orally day 1, 3, 5,
7) or in a single dose regimen (MTX 1.0 mg/kg or 50 mg/
m2 im without folinic acid) [8,9]. A single dose regimen
was introduced to minimize side effects, to improve
patients' compliance and to reduce overall costs. MTX has
been shown to be safe with virtually no adverse effects
reported on reproductive outcome [10]. Data provided by
randomised controlled trials (RCTs) indicate that sys-
temic MTX treatment should only be used in selected
patients with EP. Important selection criteria are the EP
size, absence of fetal cardiac activity on TVS, and maxi-
mum human chorionic gonadotrophin (hCG) concentra-
tions [11,12].
Expectant management has been practiced based on the
acknowledgement that the natural course of many early
EPs is a self limiting process, ultimately resulting in tubal
abortion or reabsorption. To date, expectant management
has not been properly evaluated in RCTs in selected
patients with EP [12].
In these non-surgical treatments, the pregnancy is not
removed and as a consequence there is a remaining risk of
tubal rupture. Therefore, intensive serum hCG monitor-
ing is mandatory to detect impending treatment failure
and/or inadequately declining serum hCG concentrations
[13,14]. The risk of tubal rupture combined with the need
for meticulous follow-up is likely to cause distress in the
patient because of uncertainty about treatment outcome
[15]. Non-surgical treatment modalities may therefore
have a negative impact on the patients' health related
quality of life.
In some women presenting with suspected EP, the preg-
nancy cannot be identified on TVS [16,17]. These women
with a so called pregnancy of unknown location (PUL)
can be managed expectantly with monitoring of serum
hCG to identify whether a PUL turns out to be an intra
uterine pregnancy (IUP), an EP, a failing PUL with an une-
ventful serum hCG decline to undetectable levels, or a
persisting PUL with plateauing serum hCG concentrations
[18].
Women with a visible EP but with low and plateauing
serum hCG concentrations and women with a persisting
PUL have thus far been offered medical treatment with
MTX [17,19]. However, there is no evidence on the effec-
tiveness of MTX as compared to expectant management.
This study compares both treatment options in these par-
ticular subgroups of women, representing about 10% of
women with suspected EP.
Objective
To study whether expectant management is an alternative
to treatment with systemic MTX in a single dose im regi-
men in women with an EP and low but plateauing serumPage 2 of 6
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nancy, health related quality of life and costs.
Methods
Participating centres
This study is a multicentre randomised controlled trial in
The Netherlands and inclusion started in April, 2007.
Inclusion criteria
Hemodynamically stable patients ≥ 18 years of age, with
either a visible EP on TVS (an ectopic ring or an ectopic
mass and/or fluid in the pouch of Douglas) together with
plateauing serum hCG concentrations < 1,500 IU/L, and
those women with a PUL in combination with plateauing
serum hCG concentrations < 2,000 IU/L, are eligible for
the trial. The difference in serum hCG cut-off levels for
these two entities is based on our previous studies [5,7].
Patients with a viable EP, signs of tubal rupture, active
intra abdominal bleeding or a contra indication for MTX
(e.g. abnormalities in liver or renal function or at full
blood count) are not included.
Ethical considerations
Approval for this study was obtained from the Medical
Ethical Committee of the Academic Medical Centre and
from the Central Committee on Research involving
Human Subjects (CCMO), The Netherlands. A quality
assessment has been made and approved by three external
referees, experts from the field by the Netherlands Organ-
ization for Health Research and Development (ZonMw).
A blinded interim analysis will be performed halfway the
study by the Data Monitoring and Safety Committee. In
patients fulfilling the inclusion criteria, written informed
consent is obtained before randomisation is carried out.
Women refusing participation are registered.
Randomisation
Randomisation is performed by a web-based randomisa-
tion program, using a computer program with stratifica-
tion for hospital and serum hCG concentration (< 1,000
IU/l versus 1,000–2,000 IU/l).
Interventions
Expectantly managed women will get no specific treat-
ment.
Women in the group allocated to MTX are administered a
single MTX injection, 1 mg/kg body weight im, within 24
hours after randomisation.
All Rhesus negative women will receive 375 IE anti D im.
For pain relief, if necessary, Paracetamol is prescribed.
Patients are advised to refrain from sexual intercourse
until serum hCG is undetectable. Treatment and follow
up will be carried out in the outpatient clinic (Figure 1).
Follow up
Short term follow up
In both groups weekly serum hCG measurements will be
performed until serum hCG is no longer detectable.
Serum hCG concentrations are expressed in IU/L (conver-
sion factor to SI unit, 1.00 according to the World Health
Organization Third International Standard 75/537).
Seven days after a MTX injection liver and renal function
and full blood count are checked. Complications will be
registered in the Case Record Form.
In patients treated expectantly, treatment with systemic
MTX (single shot 1 mg/kg im) is started whenever at any
of the weekly follow up visits the serum hCG concentra-
tion has risen > 15% of the prior value. Expectant manage-
ment is continued if the serum hCG concentration falls by
> 15% of the prior value [20]. In case of a persistent pla-
teauing serum hCG concentration, defined as < 15% fall
or < 15% rise, the serum hCG concentration is assessed
after 48 hours to ensure it is not increasing. If it is increas-
ing as described above, treatment with systemic MTX as
described above is installed. Whenever hemodynamic
instability and/or clinical signs of tubal rupture (i.e.,
increasing abdominal pain in combination with falling
Flowchart METEX studyigure 1
Flowchart METEX study.
 Inclusion METEX Study:
 • Age ≥ 18 yrs
 • Ectopic pregnancy and plateauing serum hCG < 1,500 IU/L
 • PUL and plateauing serum hCG < 2,000 IU/L
Informed Consent
Randomisation
No
 Exclusion METEX study:
 • Signs of shock
 • Signs of tubal rupture/abdominal bleeding
 • Vital ectopic pregnancy
 • Contraindications for MTX
Expectant 
management
Single dose MTX 
i.m.
 • Serum hCG clearance time
 • Additional interventions
 • Tubal rupture
 • Health related quality of life
 Follow-up 6, 12, 18, 24 months
 • Desire future pregnancy
 • Spontaneous intra uterine pregnancy
 • Repeat ectopic pregnancy
 • Costs
 • Health related quality of life
 • Patient preferences
Log 
registrationPage 3 of 6
(page number not for citation purposes)
BMC Women's Health 2008, 8:10 http://www.biomedcentral.com/1472-6874/8/10haemoglobin level and signs of intra abdominal haemor-
rhage on TVS) occur, surgical intervention is carried out.
In patients treated with MTX, an additional MTX injection
is given in case the serum hCG concentration on day 7 has
declined <15% of the initial value on day 1 (start of treat-
ment) [11]. If the serum hCG concentration fails to fall by
at least 15% during any successive week of follow-up,
repeated doses of MTX are given, with a maximum of
three additional injections [21]. In case of hemodynamic
instability and/or signs of tubal rupture, i.e., increasing
abdominal pain in combination with falling haemo-
globin level and signs of intra abdominal haemorrhage on
TVS, or whenever more than four MTX injections are
required, surgical treatment is indicated.
Long term follow up
Women who have been treated with MTX are advised not
to get pregnant within three months after treatment [18].
To assess fertility in both treatment arms, patients are con-
tacted every six months for a period of 24 months, by
means of questionnaires. Questions focus on the desire
for pregnancy, unprotected sexual intercourse with a
chance of spontaneous conception, contraceptive use,
infertility treatment, and the occurrence of any pregnan-
cies and their outcomes.
Outcome measures
Primary outcome measure
The primary outcome measure is an uneventful decline of
serum hCG to an undetectable level (< 2 IU/l) by the ini-
tial intervention strategy, i.e. expectant management or a
single dose systemic MTX.
Secondary outcome measures
Secondary outcome measures are (re)interventions (addi-
tional MTX injections or surgical procedures for persistent
trophoblast and/or clinical signs), treatment complica-
tions, health related quality of life, financial costs, and
future fertility. Moreover, patients' preferences will also be
assessed.
Health related quality of life is assessed by standard self
administered psychometric questionnaires with estab-
lished viability and reliability at different time points, i.e.
before randomisation, after one week, four weeks and
three months.
Costs are expressed in direct costs with data on costs and
used resources in the participating centres.
Future fertility is defined as time to the occurrence of a
spontaneous viable IUP. A viable IUP is defined as the
presence of fetal cardiac activity at a gestational age of ≥ 12
weeks. If an IUP does not occur, follow-up ends at the last
consultation. In addition to IUP, repeat EP is also
assessed. The date of occurrence of an EP will be deter-
mined from the first day of the last menstrual period.
Patients' preferences are assessed by an online question-
naire using a discrete choice experiment (DCE) based on
characteristics of both interventions and will be compared
with a control group, recruited among women visiting the
infertility clinics of the participating hospitals.
Analysis
Data analysis is performed according to the intention to
treat principle.
Short term outcome measures are compared by calculat-
ing relative risks and their 95% confidence intervals.
Future fertility is assessed by life table analysis. Kaplan-
Meier curves are constructed, estimating the cumulative
probability of time to spontaneous IUP and repeat EP. If
a spontaneous viable IUP does not occur, follow up ends
at the last date of consultation, or at the start of in vitro
fertilisation (IVF) treatment or the date of tubal surgery.
Spontaneous conceptions that occur after failed IVF treat-
ment will be registered. The log-rank test is used to test dif-
ferences between the Kaplan-Meier curves for statistical
significance. The differences between both treatment
modalities are expressed as a fecundity rate ratio with 95%
confidence interval, calculated through Cox proportional
hazard analysis.
Changes in health related quality of life over time, and dif-
ferences between the two groups will be measured using
analysis of variance.
Depending on differences of equivalence between the
strategies, the economic evaluation will be a cost-effective-
ness analysis or a cost-minimisation analysis.
Patient's preferences are analysed by differences in out-
come of the DCE.
Power calculation
Assuming an uneventful decline of serum hCG of 60% in
the expectant management group and of 90% in the MTX
group, and assuming a power of 80% and a significance
level of 5%, 36 patients in each group are needed
[6,15,22-24].
Discussion
About 10% of women presenting with suspected EP, are
diagnosed with a visible EP but with low and plateauing
serum hCG concentrations or a persisting PUL [24]. Thus
far, these particular subgroups of women are offered med-
ical treatment with MTX based on the proven effectiveness
of systemic MTX in women with selected EPs [12,16,19].Page 4 of 6
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women at all. This RCT will provide evidence whether
expectant management is an alternative to systemic MTX
in a single dose im regimen in women with an EP with
low but plateauing serum hCG concentrations or persist-
ing PUL.
Simultaneously with our trial, another trial is ongoing in
the United Kingdom [20]. This placebo controlled trial
has a similar objective, uses the same inclusion criteria
and interventions (single shot MTX im and expectant
management). In the UK trial, however, surgical interven-
tion is installed in both treatment groups if inadequately
declining serum hCG concentrations occur after one week
of follow up. In our study, these treatment failures are
treated with additional MTX injections. In the near future,
meta analysis of the results of both trials will provide
guidance on the present management dilemmas in
women with EP or PUL with low and plateauing serum
hCG concentrations.
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